Late-onset of ornithine transcarbamylase deficiency: A rare medical examiner case.
autopsy
forensic pathology
genetic testing
hyperammonemia
liver failure
ornithine transcarbamylase
urea cycle
Journal
Journal of forensic sciences
ISSN: 1556-4029
Titre abrégé: J Forensic Sci
Pays: United States
ID NLM: 0375370
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
21
10
2021
received:
27
08
2021
accepted:
22
10
2021
pubmed:
3
11
2021
medline:
7
4
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Ornithine Transcarbamylase (OTC) is an enzyme of the urea cycle, which converts ammonia into urea in the liver cells. OTC plays a crucial role in the breakdown and removal of nitrogen in the body. OTC deficiency is a rare X-linked recessive disorder that classically presents in early life with signs of hyperammonemia and progressive central nervous system involvement resulting in seizures, coma, and death. Sentinel presentation in adulthood is quite rare. A 29-year-old man developed altered mental status after receiving an epidural steroid injection 3 days earlier for back pain. He presented to the emergency department severely agitated, and his workup revealed an elevated ammonia level of 125 µmol/L. He refused admission and was discharged against medical advice. The following day, his mentation deteriorated, he developed status epilepticus, and was transported to another emergency department. He was admitted with worsening hyperammonemia (levels rising to over 700 µmol/L). His clinical condition progressive deteriorated, and he developed encephalopathy and diffuse cerebral edema. Liver function testing indicated progressive liver damage, and amino acids were detected in his blood and urine. Clinical and laboratory findings suggested undiagnosed OTC enzyme deficiency. He died 2 days after admission. An autopsy showed an 1890 g liver with diffuse yellow discoloration and softening. Histology and electron microscopy revealed findings suggestive of urea cycle disorder, such as microvesicular steatosis, apoptosis, and scattered mitosis, clusters of clear hepatocytes at the PAS stain, and mitochondria abnormalities. Genetic analysis revealed a hemizygous pathogenic variant of the OTC gene (c.622G>A). OTC deficiency should be suspected in subjects with hyperammonemic encephalopathy. If a genetic mutation is identified in the deceased, surviving family members should be screened to prevent potential life-threatening complications.
Identifiants
pubmed: 34726276
doi: 10.1111/1556-4029.14934
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
813-819Informations de copyright
© 2021 American Academy of Forensic Sciences.
Références
McCullough BA, Yudkoff M, Batshaw ML, Wilson JM, Raper SE, Tuchman M. Genotype spectrum of ornithine transcarbamylase deficiency: Correlation with the clinical and biochemical phenotype. Am J Med Genet. 2000;93(4):313-9. https://doi.org/10.1002/1096-8628(20000814)93:4<313:aid-ajmg11>3.0.co;2-m.
Waisbren SE, Stefanatos AK, Kok TMY, Ozturk-Hismi B. Neuropsychological attributes of urea cycle disorders: a systematic review of the literature. J Inherit Metab Dis. 2019;42(6):1176-91. https://doi.org/10.1002/jimd.12146.
Shchelochkov OA, Li F-Y, Geraghty MT, Gallagher RC, Van Hove JL, Lichter-Konecki U, et al. High-frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH. Mol Genet Metab. 2009;96(3):97-105. https://doi.org/10.1016/j.ymgme.2008.11.167.
National organization for rare disorders (NORD). Ornithine transcarbamylase deficiency. 2015. http://rarediseases.org/rare-diseases/ornithine-transcarbamylase-deficiency. Accessed 24 Aug 2021.
Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 1996;335(12):855-9. https://doi.org/10.1056/NEJM199609193351204.
Lipskind S, Loanzon S, Simi E, Ouyang DW. Hyperammonemic coma in an ornithine transcarbamylase mutation carrier following antepartum corticosteroids. J Perinatol. 2011;31(10):682-4. https://doi.org/10.1038/jp.2011.23.
Summar ML, Barr F, Dawling S, Smith W, Lee B, Singh RH, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin. 2005;21(4 Suppl):S1-8. https://doi.org/10.1016/j.ccc.2005.05.002.
Atiq M, Holt AF, Safdar K, Weber F, Ravinuthala R, Jonas ME, et al. Adult onset urea cycle disorder in a patient with presumed hepatic encephalopathy. J Clin Gastroenterol. 2008;42(2):213-4. https://doi.org/10.1097/01.mcg.0000225628.84168.25.
Hawley RJ. Hyperammonia possibly due to corticosteroids. Arch Neurol. 2000;57(7):1085-6.
Gascon-Bayarri J, Campdelacreu J, Estela J, Reñé R. Severe hyperammonemia in late-onset ornithine transcarbamylase deficiency triggered by steroid administration. Case Rep Neurol Med. 2015;2015:453752. https://doi.org/10.1155/2015/453752.
Löfberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle: effects of glucocorticoids on protein turnover. Eur J Clin Invest. 2002;32(5):345-53. https://doi.org/10.1046/j.1365-2362.2002.00993.x.
Stout A, Friedly J, Standaert CJ. Systemic absorption and side effects of locally injected glucocorticoids. PM R. 2019;11(4):409-19. https://doi.org/10.1002/pmrj.12042.
Lamer TJ, Dickson RR, Gazelka HM, Nicholson WT, Reid JM, Moeschler SM, et al. Serum triamcinolone levels following cervical interlaminar epidural injection. Pain Res Manag. 2018;2018:8474127. https://doi.org/10.1155/2018/8474127.
Badizadegan K, Perez-Atayde AR. Focal glycogenosis of the liver in disorders of ureagenesis: its occurrence and diagnostic significance. Hepatology. 1997;26(2):365-73. https://doi.org/10.1002/hep.510260217.
Guicciardi ME, Malhi H, Mott JL, Gores GJ. Apoptosis and necrosis in the liver. Compr Physiol. 2013;3(2):977-1010. https://doi.org/10.1002/cphy.c120020.
Tao Y, Wang M, Chen E, Tang H. Liver regeneration: analysis of the main relevant signaling molecules. Mediators Inflamm. 2017;2017:4256352. https://doi.org/10.1155/2017/4256352.
Cheng L, Liu Y, Wang W, Merritt JL, Yeh M. Hepatocellular adenoma in a patient with ornithine transcarbamylase deficiency. Case Reports Hepatol. 2019;2019:2313791. https://doi.org/10.1155/2019/2313791.
Yamanouchi H, Yokoo H, Yuhara Y, Maruyama K-I, Sasaki A, Hirato J, et al. An autopsy case of ornithine transcarbamylase deficiency. Brain Dev. 2002;24(2):91-4. https://doi.org/10.1016/s0387-7604(01)00408-9.
Aida S, Ogata T, Kamota T, Nakamura N. Primary ornithine transcarbamylase deficiency. A case report and electron microscopic study. Acta Pathol Jpn. 1989;39(7):451-6. https://doi.org/10.1111/j.1440-1827.1989.tb02461.x.
Hostiuc S, Rusu MC, Mănoiu VS, Vrapciu AD, Negoi I, Popescu MV. Usefulness of ultrastructure studies for the estimation of the postmortem interval. A systematic review. Rom J Morphol Embryol. 2017;58(2):377-84.
Sánchez AI, Rincón A, García M, Suárez-Obando F. Urea cycle defects: early-onset disease associated with A208T mutation in OTC gene-expanding the clinical phenotype. Case Rep Genet. 2017;2017:1048717. https://doi.org/10.1155/2017/1048717.
Cavicchi C, Donati M, Parini R, Rigoldi M, Bernardi M, Orfei F, et al. Sudden unexpected fatal encephalopathy in adults with OTC gene mutations-Clues for early diagnosis and timely treatment. Orphanet J Rare Dis. 2014;9(1):105. https://doi.org/10.1186/s13023-014-0105-9.
Ploechl E, Ploechl W, Stoeckler-Ipsiroglu S, Pokorny H, Wermuth B. Late-onset ornithine transcarbamylase deficiency in two families with different mutations in the same codon: comparisons in late-onset OTC deficiencies. Clin Genet. 2001;59(2):111-4. https://doi.org/10.1034/j.1399-0004.2001.590208.x.
Middleton O, Baxter S, Demo E, Honeywell C, Jentzen J, Miller F, et al. National Association of Medical Examiners position paper: retaining postmortem samples for genetic testing. Acad Forensic Pathol. 2013;3(2):191-4. https://doi.org/10.23907/2013.024.
Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. Ornithine transcarbamylase deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews®. Seattle, WA: University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK154378. Accessed 24 Aug 2021.